Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 15;387(11):1045-1047.
doi: 10.1056/NEJMc2206449. Epub 2022 Sep 7.

Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment

Michael E Charness  1 , Kalpana Gupta  1 , Gary Stack  2 , Judith Strymish  3 , Eleanor Adams  4 , David C Lindy  5 , Hiroshi Mohri  5 , David D Ho  5
Affiliations

Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment

Michael E Charness et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Time Course of SARS-CoV-2 Infection and Covid-19 Symptoms in 13 Patients with Rebound.
Shown are data that were obtained between February 10 and May 30, 2022, from the 13 study patients. Day 0 was the first day of positive results on diagnostic testing or symptoms. The time periods are indicated for the administration of nirmatrelvir–ritonavir (N/R), symptoms, antigen tests, PCR (cycle threshold [Ct] values on polymerase-chain-reaction assay, when available), subvariant classification, and transmission. A rapid molecular test (Rapid PCR, Cue Health) was used only in the 55-year-old male patient, for whom PCR results with Ct values were obtained through BioReference Laboratories.
See this image and copyright information in PMC

Comment on

References

    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 2022;386:1397-1408. - PMC - PubMed
    1. Food and Drug Administration. Emergency use authorization (EUA) for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets). 2021. (https://www.fda.gov/media/155194/download).
    1. Hay JA, Kissler SM, Fauver JR, et al. Viral dynamics and duration of PCR positivity of the SARS-CoV-2 omicron variant. January 14, 2022. (https://www.medrxiv.org/content/10.1101/2022.01.13.22269257v1). preprint.
    1. Carlin AF, Clark AE, Chaillon A, et al. Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Clin Infect Dis 2022. June 20 (Epub ahead of print). - PubMed
    1. Boucau J, Uddin R, Marino C, et al. Characterization of virologic rebound following nirmatrelvir–ritonavir treatment for COVID-19. Clin Infect Dis 2022. June 23 (Epub ahead of print). - PMC - PubMed